A tanshinone ⅡA-based nano co-loading system, a preparation method and application thereof
By constructing a nano-co-loading system of tanshinone IIA and chemotherapy drugs, and utilizing folic acid to modify albumin and selenium nanoparticles, simultaneous drug delivery and MRP1 expression regulation were achieved. This addresses the shortcomings of existing nano-drug delivery systems in MDR regulation, and improves the efficacy of chemotherapy and the drug-likeness of traditional Chinese medicine monomers.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- DALI UNIV
- Filing Date
- 2026-06-10
- Publication Date
- 2026-07-17
AI Technical Summary
While existing nano-drug delivery systems can improve drug delivery efficiency, they are difficult to effectively regulate multidrug resistance (MDR), especially lacking effective technical solutions to increase intracellular drug accumulation and regulate resistance mechanisms mediated by MDR-related proteins.
A nano-co-loading system based on tanshinone IIA was constructed. Folic acid-modified albumin was used to participate in the construction of the nano-system. Tanshinone IIA and chemotherapy drugs were loaded into selenium nanoparticles to achieve simultaneous introduction and stable delivery of drugs. Furthermore, MDR was reversed by downregulating MRP1 expression through tanshinone IIA.
It increased the retention of chemotherapy drugs in tumor cells, reduced drug efflux, and improved the efficacy of chemotherapy. In particular, it showed significant anti-tumor activity and cytotoxicity in drug-resistant cells and improved the drug-likeness of Chinese herbal monomers.
Smart Images
Figure CN122398756A_ABST